CDK2 inhibitors(Cyclin-dependent kinase 2 inhibitors), DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors), MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors)

Therapeutic Areas

Other DiseasesNeoplasmsImmune System Diseases+ [11]

Active Indication

InflammationLocalized Prostate CarcinomaAdenocarcinoma of prostate+ [38]

Inactive Indication

Aberrant Crypt FociAdvanced cancerColitis, Ulcerative+ [4]

Originator Organization

The University of Texas MD Anderson Cancer Center

Active Organization

Seoul National UniversityFranklin Square Hospital Center, Inc.

University of Pennsylvania

+ [44]

Inactive Organization

Seattle Children's Hospital

Genzada Pharmaceuticals Usa, Inc.

The Affiliated Hospital of Qingdao University

+ [3]

License Organization-

Drug Highest PhaseApproved

First Approval Date-

RegulationOrphan Drug (United States), Orphan Drug (European Union)

Structure/Sequence

Molecular FormulaC21H20O6

InChIKeyVFLDPWHFBUODDF-FCXRPNKRSA-N

CAS Registry458-37-7

689

Clinical Trials associated with Curcumin

CTIS2025-523791-24-00

/ RecruitingPhase 1

A study investigating the effect of curcumin on the absorption and elimination of IMU 838, a new compound that may potentially be used in the treatment of multiple sclerosis, and the effect of IMU 838 on the absorption and elimination of rosuvastatin.

Start Date08 Jan 2026

Sponsor / Collaborator

Immunic AG

IRCT20251014067619N1

/ SuspendedPhase 1/2IIT

The impact of curcumin supplementation on serum levels of immunoglobulins and beta-2 microglobulin in hemodialysis patients

Start Date22 Dec 2025

Sponsor / Collaborator

Tabriz University of Medical Sciences

CTRI/2025/11/097319

/ Not yet recruitingPhase 4IIT

Assessing The Effect Of Curcumin On The Oral Mucosal Cytomorphometry And Candidal Species Specificity In Oral Submucous Fibrosis Patients- A Randomized Controlled Trial - NIL

Start Date27 Nov 2025

Sponsor / Collaborator-

100 Clinical Results associated with Curcumin

100 Translational Medicine associated with Curcumin

100 Patents (Medical) associated with Curcumin

28,576

Literatures (Medical) associated with Curcumin

31 Dec 2026·PHARMACEUTICAL BIOLOGY

A scoping review of turmeric adulteration based on data from six continents

Article

Author: Blumenthal, Mark ; Gafner, Stefan ; Orhan, Nilüfer ; Kahraman, Çiğdem

CONTEXT:

Turmeric (Curcuma longa) is widely used as a spice and in dietary/food supplements and herbal medicines. Reports assessing the authenticity of commercial products have shown that the ingredient is subject to adulteration with, among others, artificial dyes, undeclared diluents, and synthetic curcumin.

OBJECTIVE:

This scoping review summarizes published data on adulteration of turmeric products sold as spice and dietary or food supplements to estimate the prevalence of non-authentic turmeric on the market.

METHODS:

This scoping review was based on a literature analysis from Google Scholar, PubMed, ScienceDirect, Scopus, and Web of Science databases, covering publications from 2000 to 2025. Article selection was performed according to PRISMA-ScR guidelines. After the initial search, specific countries were added to refine the search. Of the 375 publications retrieved, 347 were eliminated as duplicates or because they lacked information on turmeric adulteration, adulteration of commercial products, or did not provide the number of adulterated samples. An additional 19 papers were found searching the citations, or by using Google Search with the keywords "Curcuma longa", "turmeric", "government report", and "adulteration". One more report from the CVUA Stuttgart was found using the keywords "Kurkuma", "Verfälschung", and "Report". In total, 48 papers were included in the review.

RESULTS:

A total of 48 publications representing 2235 commercial turmeric samples were included in the study. The overall adulteration rate was 20.0%, with spice samples having a slightly lower percentage of adulterated samples (20.4%) than dietary and food supplements (22.0%).

CONCLUSION:

Adulteration of turmeric remains a concern on markets worldwide.

31 Dec 2026·DRUG DELIVERY

Long-term management of psoriasis recurrence via modulation of cutaneous microbiome: synergistic topical therapy with blue light and aptamer-functionalized curcumin formulation

Article

Author: Li, Bingbing ; Chen, Jianmin ; Zheng, Tingting ; Weng, Yumin ; Lin, Xin ; Jin, Nan ; Liu, Tianhui ; Su, Yanhong ; Chen, Yaling ; Luo, Huangyu

The recurrence following the discontinuation of medication is a formidable challenge in managing psoriasis. Changes in the microbiome accompany the onset of psoriasis relapse, highlighting a potential therapeutic modality. To evaluate the superiority of the topical administration of aptamer-functionalized curcumin mesoporous silica (Apt-GA+Cur@μmS) plus blue light (BL) in restoring dysbiosis and intervening in recurrence in a murine model, a psoriasis relapse murine model with double imiquimod induction was established. With a BL-responsive shell, Apt-GA+Cur@μmS released curcumin (Cur) to assist BL to improve the preventative and therapeutic effects in the psoriasis relapse murine model, as evidenced by the psoriasis area and severity index, histology, splenic index, and dorsal IL-17A level. We also observed a negative correlation between splenic nitric oxide (NO) levels and the splenic index, indicating a possible mechanism by which Apt-GA+Cur@μmS&BL may function in the treatment of splenomegaly. Treatment with Apt-GA+Cur@μmS&BL exhibited a higher alpha diversity than the model group, with levels similar to those of healthy mice, indicating that this combination could adjust the composition of the dorsal microbiome to a healthier state. A reduction in the combined relative abundance of Staphylococcus, Streptococcus, and Corynebacterium as well as restoration of dysbiosis was also verified through 16S rDNA gene sequencing in vivo. Collectively, BL and Apt-GA+Cur@μmS cotherapy alleviates psoriasiform lesions in a double imiquimod-induced murine model by inhibiting IL-17A and increasing splenic NO. Additionally, this cotherapy restores the eubiosis of the dorsal lesions. Thus, it is a promising and innovative therapeutic modality for psoriasis inflammation alleviation and recurrence intervention.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Comparison the effect of Curcumin and methanolic extracts of Fraxinus excelsior L. and glycyrrhiza glabra L. on the expression of MexCD-OprJ and MexEF-OprN efflux pumps in multidrug resistant Pseudomonas aeruginosa clinical isolates

Article

Author: Goli, Hamid Reza ; Gholami, Mehrdad ; Jamal, Zeynab ; Ebrahimzadeh, Mohammad Ali

BACKGROUND:

Pseudomonas aeruginosa is a multidrug-resistant (MDR) pathogen, and efflux pumps such as MexCD-OprJ and MexEF-OprN play a key role in its antibiotic resistance. This study evaluated the putative effects of curcumin and methanolic extracts of F. excelsior L. and G. glabra L. on the expression of these efflux pumps, as well as their role in mediating antibiotic resistance.

METHODS AND RESULTS:

In this study, MDR P. aeruginosa clinical strains were used to determine the minimum inhibitory concentrations (MICs) of tobramycin and ciprofloxacin in the presence and absence of curcumin and selected plant extracts (F. excelsior L. and G. glabra L.) and curcumin. Real-time PCR was used to assess changes in efflux pump gene expression in tested strains. A significant positive correlation was identified between resistance to the tested antibiotics and increased expression of MexCD-OprJ and MexEF-OprN, as determined by Spearman's rank correlation using SPSS (p < 0.05). Treatment with the extracts, individually and in combination, resulted in a reduction in the expression levels of both efflux genes (p < 0.05), with the combined treatment showing the greatest effect. These findings were supported by colony count and turbidity assays, as evidenced by > 80% reduction in viable counts and decreased turbidity in treated groups.

CONCLUSION:

Overexpression of MexCD-OprJ and MexEF-OprN is a key factor contributing to MDR in P. aeruginosa. Treatment with curcumin, F. excelsior L. and G. glabra L. extracts-especially in combination, suggesting potential for suppression of efflux gene expression and enhanced antibiotic efficacy.

News (Medical) associated with Curcumin

28 Jan 2026

·www.prnewswire.com

CMUH-Ever Supreme Team Develops World-First Brain-Targeting Exosome Delivering Curcumin Across the Blood-Brain Barrier for Parkinson's Disease

TAICHUNG, Jan. 28, 2026 /PRNewswire/ -- China Medical University Hospital (CMUH), under the leadership of Superintendent Dr. Cho Der-Yang, announced a major breakthrough in exosome-based drug delivery, achieved in collaboration with Ever Supreme Bio Technology and Shine-On Biomedical. Building on their prior success in developing HLA-G–targeted exosomes for solid tumors, the research team has now extended this advanced platform into the highly challenging domain of the central nervous system (CNS). Continue Reading The research team led by Dr. Cho Der-Yang, Superintendent of China Medical University Hospital, in collaboration with Ever Supreme Bio Technology and Shine Out Biotechnology, jointly unveiled the world’s first actively navigated αDAT-EV Brain-Targeting Exosome Platform. (From left to right: Mr. Lee Ming-Juan, Vice General Manager of Shine Out Bio Technology; Academician Dr. LIN Jaung-Geng of Academia Sinica; Dr. Cho Der-Yang, Superintendent of China Medical University Hospital.) The result is a world-first, actively navigated brain-targeting exosome platform—αDAT-EV—capable of transporting therapeutic agents across the blood–brain barrier (BBB) and precisely directing them to impacted neural regions implicated in Parkinson's disease (PD). This landmark research has been published in the leading international publication Journal of Nanobiotechnology. αDAT-EV: The World's First Actively Navigated Brain-Targeting Exosome Drug Delivery Platform Dr. Cho noted that as global populations age, the prevalence of neurodegenerative diseases such as Parkinson's disease continues to rise sharply. Yet for decades, neurological therapeutics have faced a formidable obstacle: nearly 98% of drugs fail to effectively cross the blood–brain barrier, severely limiting treatment efficacy and slowing progress in neurological medicine. To overcome this bottleneck, CMUH researchers, together with Shine Out Bio Technology, employed genetic engineering techniques to modify antibody fragments on the surface of exosomes that recognize the dopamine transporter (DAT). This innovation enables αDAT-EVs to actively identify and target dopaminergic neurons—effectively equipping therapeutic agents with a GPS-like navigation system that directs them to diseased brain regions while improving the bioavailability of small-molecule drugs. A Nano-Scale " Medicinal Guide ": Reimagining Curcumin with Modern Biotechnology Academician Dr. Lin Jaung-Geng of Academia Sinica explained that curcumin, long revered in traditional medicine as a "food-medicine homolog," is known for its antioxidant and anti-inflammatory properties. Modern research has confirmed its ability to repair neuronal damage at the source and clear pathological protein aggregates. Despite its promise, the benefits of curcumin have historically been "visible but unattainable": poor water solubility, rapid metabolism, and inability to cross the blood–brain barrier have resulted in negligible brain concentrations in clinical settings. Through the αDAT-EV brain-targeting platform, curcumin can now be actively guided into the brain, functioning as a modern nano-scale medicinal guide. This breakthrough exemplifies the integration of traditional medical wisdom with cutting-edge biotechnology, and stands as a compelling model for the scientific modernization of traditional medicine. Multi-Pathway Cellular Repair Demonstrates Strong Translational Potential According to Mr. Lee Ming-Juan, Vice General Manager of Shine Out Bio Technology, preclinical studies using αDAT-EVs loaded with curcumin have demonstrated promising therapeutic effects in both cellular and animal models, highlighting the platform's potential as a next-generation nano drug carrier: 1. Precision Targeting The platform significantly enhances drug penetration across the BBB and enriches therapeutic agents in key Parkinson's disease-related regions, including the substantia nigra and ventral tegmental area. 2. Activation of Repair Mechanisms αDAT-EVs trigger cellular autophagy-lysosomal pathways and mitochondrial repair mechanisms, effectively clearing pathological α-synuclein aggregates and alleviating disease symptoms. 3. Immune Modulation The treatment promotes a shift in brain microglia from a pro-inflammatory to a reparative phenotype, indicating reduced neuroinflammation. 4. Improved Motor Function Parkinson's disease animal models exhibited marked recovery in motor coordination, underscoring the platform's strong clinical translation potential. A Versatile Exosome Platform Expanding the CNS Therapeutic Frontier The αDAT-EV brain-targeting exosome platform is highly scalable and expandable. While initially developed to deliver cytotoxic payloads against cancer cells, it now demonstrates the ability to transport therapeutic agents for neuronal repair. This innovation offers a transformative solution for neurodegenerative diseases long constrained by the blood–brain barrier. Looking ahead, the platform may be adapted to deliver small-molecule drugs, nucleic acid therapies (mRNA), or protein-based therapeutics, with potential applications in Alzheimer's disease, stroke, and other CNS disorders, significantly advancing the fields of neurology and precision medicine. In the fourth quarter of 2025, Ever Supreme Bio Technology announced the acquisition of 100% equity in Shine Out Bio Technology through a share-exchange transaction, resulting in Shine Out becoming a wholly owned subsidiary. The effective date of the share s January 13, 2026. General Manager Mr. Huang Wen-Liang stated that the acquisition creates strong synergies between the two companies' technology platforms and therapeutic focus areas, accelerating the advancement of cell-based therapies into an internationally competitive pharmaceutical industry regulated under Taiwan's Regenerative Medicine Act and the Regenerative Medicine Products Act. Under Taiwan's Regenerative Medicine Dual-Act framework, beginning January 1, 2026, regenerative products targeting life-threatening or severely disabling diseases may apply for a conditional five-year marketing authorization upon completion of Phase II clinical trials demonstrating safety and preliminary efficacy. This pathway significantly accelerates commercialization and promises improved therapeutic options for aging societies worldwide. Note 1: Shine Out Biotechnology is dedicated to developing next-generation exosome drug delivery platforms. Leveraging proprietary genetic engineering and manufacturing technologies, the company addresses longstanding challenges in exosome yield and targeting specificity. With "precision delivery and regenerative repair" at its core, Shine-On aims to become a global leader in exosome-based therapeutics. Note 2: Journal of Nanobiotechnology. SOURCE China Medical University Hospital 21% more press release views with Request a Demo

AcquisitionPhase 2

08 Jan 2026

·www.prnewswire.com

The Science and Innovation Behind Jubileye Health: A Breakthrough in Dry Eye & Glare Defense

How advanced research and clinically studied ingredients are redefining eye comfort and visual clarity. ALICE, Texas, Jan. 8, 2026 /PRNewswire/ -- Jubileye Health Dry Eye & Glare Defense represents a breakthrough in ocular wellness, built on cutting-edge research and clinically studied ingredients that target the root causes of eye discomfort. Unlike traditional solutions that only offer temporary relief, Jubileye's formulation leverages osmolytes for cellular hydration, hyaluronic acid for tear-film stability, and visual antioxidants like lutein and zeaxanthin for glare protection—all delivered in a clean-label, omega-3-free capsule designed for maximum bioavailability. Continue Reading Jubileye Health Dry Eye and Glare Defense is a 2-in-1 solution-hydration + glare support-delivered in a clean label, omega-3-free capsule. You get meaningful doses of osmolytes, hyaluronic acid, electrolytes, and visual antioxidants (lutein/zeaxanthin, astaxanthin, bilberry) with clinically studied ingredients and meaningful doses. Our Jubileye Eye Health supplement is made with science-driven ingredients that support the eyes from the inside out.. This science-driven approach ensures comprehensive support for all three layers of the tear film, helping consumers achieve lasting eye comfort and visual clarity from the inside out. Why Cellular Hydration Matters in Dry Eye While many dry eye solutions focus on reducing tear evaporation or supplementing surface moisture, emerging research suggests that dry eye symptoms often begin when corneal surface cells lose water and struggle to maintain proper osmotic balance. When cells are dehydrated, the tear film can become unstable—even when oil production is adequately addressed and artificial tears are applied regularly. Jubileye Health incorporates osmolytes such as betaine, which are known to help cells regulate water balance and protect against environmental and metabolic stress. This cellular hydration support is complemented by hyaluronic acid and electrolytes, which help reinforce tear-film stability and moisture retention—creating a more resilient ocular surface from the foundation up. The Innovation Behind Jubileye Jubileye Health's 2-in-1 formula combines hydration support and glare defense in a single capsule. Its proprietary blend includes: Osmolytes (Betaine) for cellular hydration and osmotic balance Hyaluronic Acid & Electrolytes for tear-film stability Visual Antioxidants such as lutein, zeaxanthin, astaxanthin, and bilberry for glare protection and retinal support Bioavailability Enhancers like phytosomal curcumin for optimal absorption Manufactured in the USA in a cGMP-certified facility, Jubileye Health delivers clinically studied ingredients in meaningful doses, ensuring quality and safety for consumers seeking a science-backed approach to eye health. "Our goal was to create a solution that goes beyond surface-level relief," said Dr. Raymund Garza, optometrist and creator of Jubileye Health Dry Eye and Glare Defense. "By focusing on cellular hydration, osmotic balance, and antioxidant protection, we've developed a formula that supports eye comfort from the inside out. Patients wanted a clean, omega-3-free option that truly works—and Jubileye delivers exactly that." Looking Ahead Jubileye Health is committed to ongoing research and innovation in ocular wellness. Future developments will continue to leverage advanced science to help consumers protect and enhance their vision in an increasingly digital world. Availability: Jubileye Health Dry Eye & Glare Defense is now available for purchase at . For more information, images, or to schedule an interview with Dr. Garza, please call (361) 668-3937 or email: [email protected]. SOURCE Jubileye Health 21% more press release views with Request a Demo

08 Jan 2026

·www.sciencedaily.com

Long COVID may be fueled by inflammation and tiny clots

Long COVID affects an estimated 65 million people worldwide and can damage the brain, heart, blood vessels, and immune system long after infection. Researchers now link symptoms to lingering virus, inflammation, micro-clots, and disrupted energy metabolism. While structured rehab and pacing can improve quality of life, a growing list of experimental treatments—from antivirals and metformin to microbiome therapies and biologics—shows early promise. Clear answers, however, are still limited by small studies and the lack of large, definitive trials.Long COVID is defined as symptoms that last at least two months after an initial SARS-CoV-2 infection, with no other clear medical explanation. An estimated 65 million people worldwide are now affected, yet there are still no approved, evidence-based treatments. Researchers are working to better understand what drives the condition and to test a wide range of possible therapies, from structured rehabilitation programs to antivirals, blood thinners, anti-inflammatory drugs, supplements, and new biologic treatments. Scientists believe long COVID is fueled by several overlapping biological problems. These include lingering virus in the body, ongoing low-level inflammation marked by elevated IL-1β, IL-6, and TNF-α, and the formation of tiny blood clots caused by interactions between the viral spike protein and fibrinogen. Other contributing factors include auto-immunity, disruptions in gut bacteria, and impaired mitochondrial function. Together, these processes can damage multiple organs, leading to blood vessel dysfunction, heart inflammation, neuro-inflammation, small-fiber neuropathy, ME/CFS-like fatigue, menstrual changes, problems with blood sugar regulation, and kidney or liver injury. Rehabilitation and Non-Drug Approaches For people with mild symptoms in the early stages, non-drug treatments remain the first option. Clinical trials show that online, group-based physical and mental rehabilitation programs can improve quality of life. Breathing exercises and inspiratory-muscle training have also been shown to boost heart and lung fitness. Additional strategies may include pacing daily activities, cognitive and speech therapy, smell retraining, and dietary counseling. However, exercise that is not carefully supervised can worsen inflammation. For this reason, activity programs need to be gradual and adjusted based on symptoms. Antivirals and Early Treatment Effects Antiviral drugs taken during the initial COVID-19 infection appear to slightly reduce the risk of developing long COVID. In Japan, ensitrelvir lowered long-COVID rates by 25% among out-patients. In high-risk individuals, nirmatrelvir/ritonavir and molnupiravir were linked to about a 25% reduction in risk, while favipiravir showed little benefit. Researchers are also studying monoclonal antibodies that target the spike protein for possible effects on neuro-toxicity, although phase-3 trial results are not yet available. Medications Targeting Specific Symptoms Some treatments focus on particular complications such as clotting, autonomic nervous system problems, and immune imbalance. Low-dose naltrexone has been shown to reduce fatigue and lower platelet aggregation. Apheresis can remove micro-clots and auto-antibodies from the blood, but it is expensive and its benefits tend to be short-lived. Other medications are being tested for symptom relief. β-blockers are used to treat postural-tachycardia syndrome. Famotidine, intravenous immunoglobulin, SGLT-2 inhibitors, and GLP-1 agonists are under investigation for neurological, immune-related, heart, and kidney symptoms. Targeting Inflammation at Its Source Reducing inflammation early appears to be one of the most active areas of research. When started within seven days of infection, metformin lowered the risk of long COVID by 41%, likely by reducing mTOR signaling. Plant-based supplements containing quercetin, curcumin, and piperine improved fatigue compared with placebo. Other approaches include sulphur-thermal-water inhalation and enzymatically liberated salmon oil, both of which lowered CRP levels and helped restore the lung's protective barrier. Baricitinib and rapamycin, which act on JAK and mTOR pathways, are now entering multi-centre trials aimed at interrupting widespread STAT3-driven inflammation. Gut Health, Supplements, and Energy Metabolism Adjusting the gut microbiome may also help. The synbiotic SIM01 eased overall symptoms after six months. Small randomized trials suggest that high doses of vitamins C and D, coenzyme Q10, magnesium, and creatine-glucose blends can improve cellular energy production and blood vessel function. Early-stage studies also report benefits from N-acetyl-cysteine and the amino-acid blend AXA1125, both of which improved mitochondrial respiration and reduced fatigue. Experimental Biologics and Emerging Therapies New biologic treatments are exploring the role of fibrin-driven neuro-inflammation. A humanized antibody that blocks the inflammatory region of fibrinogen is currently in phase-1 trials after animal studies showed protection against neuronal loss. Another experimental therapy, the DNA aptamer BC007, removes G-protein-coupled-receptor auto-antibodies and reversed fatigue and poor capillary blood flow in a single patient, though larger trials are still needed. Other non-drug approaches have shown potential. Hyperbaric oxygen therapy improved cognition, sleep, and pain in a six-month randomized trial. Case series of acupuncture reported reductions in brain-fog and joint pain. Vaccines and Long COVID Outcomes Vaccination provides limited protection against long COVID after breakthrough infections, lowering risk by about 15 to 41%. Among people who already had long COVID symptoms, outcomes after a booster were mixed. About 17% improved, 21% worsened, and 62% saw no change. Where the Science Stands Now Although many potential treatments are showing early promise, most evidence still comes from small or open-label studies that rely on indirect outcome measures. Large, adaptive randomized trials with consistent definitions and biomarker-based patient grouping are urgently needed. Until clearer answers emerge, experts support a flexible, team-based approach that includes early antiviral use, carefully graded exercise, targeted anti-thrombotic and anti-inflammatory treatments, gut microbiome support, and personalized rehabilitation. This strategy reflects the diverse, multi-system nature of long COVID while researchers continue searching for definitive, mechanism-based cures.

Clinical ResultPhase 1Phase 3AHA

100 Deals associated with Curcumin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Curcumin	-	DB11672

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Inflammation	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Localized Prostate Carcinoma	Phase 3	United States	The University of Texas Southwestern Medical Center	11 Mar 2019
Crohn Disease	Phase 3	France	3i Nature SAS	01 Dec 2014
Adenocarcinoma of prostate	Phase 3	United States	The University of Texas Southwestern Medical Center	01 May 2014
Colorectal Cancer	Phase 3	-	University of Pennsylvania	-
Colorectal Cancer	Phase 3	-	The University of Texas MD Anderson Cancer Center	-
Conjunctivitis, Allergic	Phase 3	-	The University of Texas MD Anderson Cancer Center	-
Conjunctivitis, Allergic	Phase 3	-	University of Pennsylvania	-
Optic Atrophy, Hereditary, Leber	Phase 3	-	University of Pennsylvania	-
Optic Atrophy, Hereditary, Leber	Phase 3	-	The University of Texas MD Anderson Cancer Center	-
Stomatitis	Phase 3	-	University of Pennsylvania	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ACR2024	Not Applicable	Osteoarthritis	106	Supplement combination	bzarjrbosi(myediolauq) = yrxshjdymn abennlbvbv (ogwndjonxo, -14.35 to -2.92)	Negative	10 Nov 2024
				Placebo	bzarjrbosi(myediolauq) = czbravuqvq abennlbvbv (ogwndjonxo, -20.94 to -8.32)
NCT02944578 (CTgov)	Phase 2	Uterine Cervical Dysplasia \| Cervical Intraepithelial Neoplasia	7	Curcumin (Curcumin)	lytyoqoqbn = kpvjkbnfen nbpgibugxa (gzpollpnll, ifkjapbccd - achfctunld) View more	-	29 Oct 2024
				placebo (Placebo)	lytyoqoqbn = ouhavdqsbe nbpgibugxa (gzpollpnll, qdzqyltyld - clwgvrjgmu) View more
NCT03223883 (CTgov)	Phase 2	Cognitive Dysfunction \| Chronic Kidney Diseases	94	Curcumin (Curcumin)	kjfvriwwqb(mxrmbgpmlj) = oxgoakvgui mzaoudvtsr (huqnjqsuxe, nsprmphlyd - dvcqxsmzeh) View more	-	08 Oct 2024
				Placebo (Placebo)	kjfvriwwqb(mxrmbgpmlj) = madkdmxmxu mzaoudvtsr (huqnjqsuxe, usrkspfyfl - ojxaniwvnm) View more
NCT04205929 (CTgov)	Phase 4	Hemorrhage \| Metrorrhagia	58	Placebo (Placebo Group)	yyqeexotnq(aywlmeohmq) = jyxizplspd mwezxpzfhj (mbdncjvpow, 4.8) View more	-	03 Jul 2024
				Curcumin (Curcumin Group)	yyqeexotnq(aywlmeohmq) = axletgxylk mwezxpzfhj (mbdncjvpow, 6.9) View more
NCT02100423 (CTgov)	Phase 2	Chronic Lymphocytic Leukemia \| B-Cell Lymphoma \| Small Lymphocytic Lymphoma	35	pharmacological study+cholecalciferol+Curcumin	bvanquchgd = nbltmfltub pospqwlbst (xrrsyafucg, jsxxswwthv - ramyfagcsu) View more	-	12 Apr 2024
NCT02782949 (CTgov)	Phase 2	Carcinogenesis \| Gastritis, Atrophic \| Stomach Cancer	50	Quality-of-Life Assessment+Curcumin (Arm I (Curcumin))	gozbzwqemd(puomjtakfo) = pklzcvhtgx alumolowal (hffuwqmfkl, bychbyahzh - tihqhldfas) View more	-	05 Mar 2024
				Quality-of-Life Assessment (Arm II (Placebo))	gozbzwqemd(puomjtakfo) = eqsbdfsqny alumolowal (hffuwqmfkl, ppgquogzsf - kxvfehuccp) View more
NCT02494141 (CTgov)	Phase 4	Polycystic Kidney, Autosomal Dominant \| Ischemic Attack, Transient	68	Curcumin (Curcumin)	xyvchqkqfm(xnkpugiwbp) = vizbyvbeev voalcaiiqj (qiqtsksqzv, dalvfucste - tqpisszhkn) View more	-	03 Mar 2022
				Placebo (Placebo)	xyvchqkqfm(xnkpugiwbp) = ovparnugyk voalcaiiqj (qiqtsksqzv, xjfazzhnfd - zkazkpxkgv) View more
NCT03085680 (SPICE, CTgov)	Phase 2/3	Cognition	17	Curcumin (Curcumin)	xmlabwtnps(wvlcufsvzt) = txiytjgwxo mfzanfnfnv (xvcamvhhka, 0.090) View more	-	02 Feb 2022
				microcrystalline cellulose (Placebo)	xmlabwtnps(wvlcufsvzt) = ygwfqddivd mfzanfnfnv (xvcamvhhka, 0.10) View more
NCT02494141 (Pubmed \| Clin J Am Soc Nephrol)	Phase 4	Polycystic Kidney, Autosomal Dominant	68	Curcumin supplementation	rjfxioqxsk(cphzymohdy) = bgojoqqldg rwwabesxqv (zjrylmqrdi ) View more	Negative	14 Dec 2021
				Placebo	rjfxioqxsk(cphzymohdy) = aegosftuox rwwabesxqv (zjrylmqrdi ) View more
NCT01514370 (Pubmed \| Mult Scler Relat Disord)	Phase 2	Multiple sclerosis relapse Add-on	80	IFN-curcumin	lumkrrrflq(uedpsdenqe) = jeajbqtilz lkylghlato (kmukcgdlrz )	-	21 Sep 2021
				IFN-placebo	lumkrrrflq(uedpsdenqe) = vrzjqrnttp lkylghlato (kmukcgdlrz )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Curcumin

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation